

Trust Headquarters  
 Russells Hall Hospital  
 Dudley  
 West Midlands  
 DY1 2HQ

**Ref:** FOI-112025-0002019

**Date:** 13.11.25

**Address / Email:**

Dear

**Request Under Freedom of Information Act 2000**

Thank you for requesting information under the Freedom of Information Act 2000.

**Request**

1. Please provide Hemophilia A patient numbers broken down by: age, disease severity and treatment regimen (PPx denotes use for prophylaxis and OD denotes use on demand). I have proposed a format below to capture the relevant information. If data is not available by age breakdown, then please provide aggregated total in the yellow highlighted column:

July through September 2025	Age											
Brand name (scientific)	0-12 years						13+					
	Mild		Moderate		Severe		Mild		Moderate		Severe	
	PPx	OD	PPx	OD	PPx	OD	PPx	OD	PPx	OD	PPx	OD
Hemlibra (emicizumab)												
Altuvect (giroctocogene fitelparvovec)												
Esperoct (turoctocog alfa pegol)												
Elocta (efmoroctocog alfa)												
Advate (octocog alfa)												
Kovaltry (octocog alfa)												
Iblias (octocog alfa)												
Refacto AF (moroctocog alfa)												
Xyntha (moroctocog alfa)												
NovoEight (turoctocog alfa)												

Nuwiq (simoctocog alfa)												
Vihuma (simoctocog alfa)												

**Inhibitor patients**

2. For Hemlibra-treated **Hemophilia A Inhibitor** patients, please indicate the number of patients by age group and dosing frequency for Q3'25 (July–September 2025). If data is not available by age breakdown then please provide aggregated total:

Age group (Hemophilia A inhibitor patients)	Once weekly	Every 2 weeks	Every 4 weeks
0-12 years			
13+ years			
Total			

**Non-inhibitor patients**

3. For Hemlibra-treated **Hemophilia A non-inhibitor** patients, please indicate the number of patients by age group and dosing frequency for Q3'25 (July–September 2025). If data is not available by age breakdown then please provide aggregated total:

Age group (Hemophilia A non-inhibitor patients)	Once weekly	Every 2 weeks	Every 4 weeks
0-12 years			
13+ years			
Total			

**Response**

This information would be held by the Pathology Department.

The Black Country Pathology Services (BCPS) Partnership integrates pathology services and is based at The Royal Wolverhampton NHS Trust (RWT) for Sandwell West Birmingham Hospitals NHS Trust (SWBH), The Dudley Group NHS Foundation Trust (DGH) and Walsall Healthcare NHS Trust (WHT). The Black Country Pathology Service is hosted by RWT on behalf of the Partnership.

Therefore, please can you forward your request to The Royal Wolverhampton NHS Trust [rwhttr.FOI@nhs.net](mailto:rwhttr.FOI@nhs.net)

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager  
Trust Headquarters  
Russell's Hall Hospital  
Dudley  
West Midlands  
DY1 2HQ  
Email: [dgft.dpo@nhs.net](mailto:dgft.dpo@nhs.net)

FOI/REF -

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office  
Wycliffe House  
Water Lane  
Wilmslow  
Cheshire  
SK9 5AF  
Tel: 0303 123 1113  
[www.ico.org.uk](http://www.ico.org.uk)

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

**Freedom of Information Team**  
**The Dudley Group NHS Foundation Trust**